Latest posts tagged with #CTSM on Bluesky
Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.
🎥 Watch: buff.ly/kWn5KkI
#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate
At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.
🎥 Watch: buff.ly/vLWxnoe
#BCSM #CTSM #TrialUpdate #Oncology
At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.
Click here to watch:
🎥 buff.ly/Ut0Ne7p
#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky
🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.
Watch here ➡️ buff.ly/E4FLjXD
#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25
Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease
🎥 buff.ly/dLhijGf
#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25
Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.
💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC
🎥 buff.ly/r3AwOkw
#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social
Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.
Watch here:
👉 buff.ly/6GUNfkY 👈
#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors
🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure
🎥 buff.ly/ozWqgdG
#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25
Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.
💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk
#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.
Click to watch:
👉 buff.ly/RVZjPoG 👈
#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky
Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25
🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT
🎥 Watch: buff.ly/dIMvnoC
@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe
At #ESMO25, Shigehira Saji shares new MonarchE data on Ki-67 as a biomarker in HR+/HER2– high-risk #BreastCancer:
📊 High Ki-67 = ↑ recurrence risk
💊 Abemaciclib + ET effective across all Ki-67 subgroups
✅ Broad benefit, regardless of Ki-67 change
🎥 Watch: buff.ly/F1mziDY
#BCSM #CTSM #TrialUpdate
At #ESMO25, Scott Tagawa, MD, MS, FACP, discusses the Phase III PSMAddition trial in PSMA-positive mHSPC:
💥 Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI improved rPFS
📈 OS trend & manageable safety
✅ No major QoL impact
🎥 Watch: buff.ly/vSBfVPS
@myesmo.bsky.social #PCSM #UroOnc #UroSoMe #RadOnc #CTSM
We recently spoke with Karthik Ramasamy, who shared insight into the DREAMM-9 trial, aimed at optimizing the dose of belantamab mafodotin for the treatment of transplant-ineligible newly diagnosed #MultipleMyeloma.
Watch here: 👉 buff.ly/szIDc29
#Myeloma #MMSM #HemOnc #CTSM #TrialUpdate #MedSky
Want to hear findings from the EPCORE NHL-2 trial evaluating epcoritamab plus intensive chemo for patients with R/R #DLBCL eligible for autoSCT?
Watch our interview with Marek Trněný of @charlesuni.cuni.cz from #SOHO2025:
👉 buff.ly/GHh6dYG 👈
#LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
In an interview from #IMS25, Charlotte Pawlyn of @icr.ac.uk outlines ongoing UK-based clinical trials in #MultipleMyeloma, namely the FiTNESS and iFit trials.
Click here to learn more:
👉 buff.ly/3qAkNKA
#MMSM #HemOnc #CTSM #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social
Watch our interview from #IMS25 with Larry Anderson to hear about the updated safety and efficacy data from the randomized Phase III AURIGA study.🩸
Click here:
🎥 buff.ly/TclKlrd
#CTSM #TrialUpdate #MMsm #Myeloma #HemOnc #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:
🎥 buff.ly/0IeuM2Z
@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc
⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS:
🎥 buff.ly/FJvSAAR
@ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc
⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:
➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...
🎥 buff.ly/0R25Yjb
#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc
Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸
Watch now:
🎥 buff.ly/zBD1MpN
#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc
It's always a pleasure to catch up with Hermann Einsele!😊
At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸
Click here to watch the interview:
👉 buff.ly/Bc1gG2R 👈
#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social
🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:
👉 buff.ly/Z3WVJCU 👈
#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc
⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use:
🎥 buff.ly/kF09jHH
#EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm
⭐ Michael Gnant, MD, FACS, reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms:
🎥 buff.ly/hfp5orD
@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #CTSM #TrialUpdate
🎥 Ranjit Nair of @mdanderson.bsky.social shares the promising results of a Phase I study evaluating surovatamig (AZD0486), a CD19-targeting bispecific T-cell engager, in patients with R/R #NonHodgkinLymphoma:
🎥 👉 buff.ly/k5zLkkg
#SOHO2025 #LYMsm #Lymphoma #CTSM @societyofhemonc.bsky.social
